Vaxcyte, INC Form 4 insider transactions

Vaxcyte's Chief Operating Officer, Jim Wassil, executed sales of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte CEO Grant Pickering sold shares of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold a portion of his holdings on March 18, 2024, under a pre-arranged trading plan.

Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., reports acquisition of shares via restricted stock units and disposition of shares to cover tax obligations.

Vaxcyte's CEO, Grant Pickering, executed stock options and reported changes in his beneficial ownership, including shares held directly and indirectly through children's trusts.

Vaxcyte's Chief Operating Officer, Jim Wassil, reported the acquisition and disposition of company stock, including the grant of stock options and sales under a pre-arranged trading plan.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., reports the acquisition and disposal of common stock and stock options.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports the acquisition and disposal of company stock and derivative securities.

Andrew Guggenhime, CFO of Vaxcyte, Inc., reports acquisition of stock options and restricted stock units, as well as disposition of shares to cover tax obligations.

Grant Pickering, CEO of Vaxcyte, Inc., reports acquisition of stock options and restricted stock units, as well as sales of common stock, including transactions made under a 10b5-1 trading plan.

Grant Pickering, CEO of Vaxcyte, Inc., exercised stock options and sold shares of common stock on February 23 and 26, 2024, according to a Form 4 filing with the SEC.